AN INNOVATIVE REUSABLE ELECTRONIC INJECTION DEVICE FOR CERTOLIZUMAB PEGOL- RESULTS FROM A PILOT MARKET RESEARCH STUDY EXAMINING PATIENT PREFERENCE AND SATISFACTION

Author(s)

Pouls B1, Kristensen LE2, Petersson M3, van den Bemt BJ4, van Bracht E5, Bruggraber R6, Mountian I7, Wiegratz S8, Karlen H9, Ballerini L10, Jørgensen TS2
1Sint Maartensliniek and Radboud University Medical Center, Ubbergen, GE, Netherlands, 2The Parker Institute, Copenhagen, Denmark, 3Linkoping University, Sweden, Sweden, 4Sint Maartensliniek and Radboud University Medical Center, Nijmegen, Netherlands, 5UCB Pharma, Breda, Netherlands, 6UCB Pharma, Slough, UK, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Monheim am Rhein, Germany, 9UCB Pharma, Stockholm, Sweden, 10UCB Pharma, Bulle, Switzerland

Presentation Documents

OBJECTIVES

ava®, a new electromechanical injection device (e-Device) for self-injecting certolizumab pegol (CZP) has been developed with the aim of improving self-injection experience.1 The objective of this study was to assess patient experience of self-injection with the e-Device and determine patient device preference.

METHODS

Patients aged 18–85 years self-injecting CZP using a pre-filled syringe (PFS) or pre-filled pen (PFP) were recruited from the Netherlands, Denmark and Sweden. Patients completed a pre-injection assessment of self-injection (ASI) questionnaire evaluating patient self-injection perception. Following e-Device training, patients carried out three CZP injections, each two weeks apart. After each injection, patients completed a post-injection ASI questionnaire evaluating their experience. Post-ASI questions were clustered into six domains: feelings about self-injection, self-image, self-confidence, ease of use, satisfaction, and adverse reactions. Following the third injection, patients completed a preference questionnaire assessing their self-injection device preference.

RESULTS

Fifty-nine patients participated (Netherlands: 24; Denmark: 15; Sweden: 20). Patients from Sweden did not respond to all questions, therefore only preference questionnaire results are reported from Sweden. In the pre-ASI, 4/39 (10.3%) patients stated they were ‘very’ or ‘extremely’ afraid of injections, and 33/39 (84.6%) felt ‘very’ or ‘extremely’ confident self-injecting correctly with their current device. Overall, patients scored the e-Device favourably across all post-ASI domains following each injection. Across all countries, 56/59 patients answered the preference questionnaire; 32/56 (57.1%) patients chose the e-Device, 15/56 (26.8%) preferred the PFS or PFP, 9/56 (16.1%) had no preference.

CONCLUSIONS

Patients were satisfied with the e-Device preferring it to their previous devices; this suggests it may address current unmet patient needs. Including the e-Device as part of a portfolio of self-injection device options may improve patient experience.

REFERENCES

1. Domanska B. Adv Ther 2018;35:100–15.

Conference/Value in Health Info

2019-11, ISPOR Europe 2019, Copenhagen, Denmark

Code

PMD60

Topic

Medical Technologies, Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance, Medical Devices, Patient Engagement, Stated Preference & Patient Satisfaction

Disease

Biologics and Biosimilars, Medical Devices, Multiple Diseases

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×